Compare HQH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQH | MNKD |
|---|---|---|
| Founded | 1986 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2004 |
| Metric | HQH | MNKD |
|---|---|---|
| Price | $24.26 | $4.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 241.5K | ★ 4.8M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | $21.87 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $16.10 | $2.23 |
| 52 Week High | $24.85 | $6.51 |
| Indicator | HQH | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 69.16 | 56.27 |
| Support Level | $18.50 | $3.74 |
| Resistance Level | N/A | $4.55 |
| Average True Range (ATR) | 0.45 | 0.21 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 79.18 | 77.92 |
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.